NORTHFIELD, Ill., Feb. 21, 2019 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported:

Fourth Quarter Highlights

• Reported net income was $26.9 million, or $1.16 per diluted share versus $9.9 million, or $0.42 per diluted share, in the prior year. Adjusted net income was $23.7 million, or $1.02 per diluted share versus $24.6 million, or $1.06 per diluted share, in the prior year.* Prior year adjusted net income excludes a $14.9 million net after-tax charge related to the 2017 U.S. Tax Cuts and Jobs Act legislation.
  
  
  
• Surfactant operating income was $31.8 million versus $28.8 million in the prior year. This increase was primarily attributable to improved product mix and lower manufacturing costs in North America. The Company's first quarter 2018 acquisition in Ecatepec, Mexico delivered $0.8 million of operating income in the quarter. Global Surfactant sales volume increased 2% versus the prior year.
  
  
• Polymer operating income was $10.8 million versus $19.1 million in the prior year. This decrease was mostly attributable to margin pressures, lower European volume and higher expense associated with the Company's Phthalic Anhydride maintenance turnaround. Global Polymer sales volume was down 4% versus the prior year.
  
  
• Specialty Product operating income was $5.1 million versus $2.3 million in the prior year. This increase was primarily due to higher volume and improved margins in our food business and favorable order timing differences within our pharmaceutical business.

Full Year Highlights

• Reported net income was a record $112.8 million, or $4.83 per diluted share, a 23% increase versus $91.6 million, or $3.92 per diluted share, in the prior year. Adjusted net income was a record $113.8 million, or $4.88 per diluted share, a 5% increase versus $108.7 million, or $4.65 per diluted share, in the prior year.*
  
  
• 2018 marked the eighth record annual income during the last eleven years.
  
  
• The Surfactant segment delivered record operating income of $137.5 million, a 14% increase versus prior year. The Polymer segment delivered $64.5 million of operating income, a 22% decrease versus prior year. Specialty Product operating income was $11.7 million versus $10.0 million in the prior year.
  
  
• Total Company sales volume increased 3% versus the prior year. Most of the increase was attributable to higher organic Surfactant growth in the functional product and personal care end markets combined with the accretive impact of the Company's first quarter 2018 acquisition in Ecatepec, Mexico. This Surfactant growth was partially offset by lower Polymer volume.
  
  
• The Company had negative net debt at year-end as cash balances of $300 million exceeded total debt of $276 million.

"The Company delivered record results in 2018 driven by record Surfactant earnings and a lower 2018 effective tax rate," said F. Quinn Stepan, Jr., Chairman, President and Chief Executive Officer.  "The quarterly and annual Surfactant growth reflect higher sales volume, the accretive impact of our 2018 Mexico acquisition, improved North American product mix and lower manufacturing costs.  The Polymer business was down versus the prior year due to continued margin challenges and the lost share for polyisocyanurate in the European insulation market, which is still growing due to energy conservation efforts.  Our Specialty Product business results improved for both the quarter and full year."

*  Adjusted net income is a non-GAAP measure which excludes deferred compensation income/ expense as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per share.

Financial Summary

Summary of Fourth Quarter Adjusted Net Income Items

Adjusted net income excludes non-operational deferred compensation income/expense and other significant and infrequent or non-recurring items.

• Deferred Compensation: The 2018 fourth quarter reported net income includes $3.4 million of after tax income versus $1.0 million of after-tax income in the prior year.
  
  
• Business Restructuring: The 2018 fourth quarter reported net income includes $0.2 million of after-tax decommissioning expense related to our prior year Canadian plant closure. The prior year quarter included $0.8 million of after tax expense comprised of: (i) $0.2 million of decommissioning costs associated with our Canadian plant shutdown; and (ii) $0.6 million of severance related to our Fieldsboro, NJ plant restructuring.

Percentage Change in Net Sales

The 2% decrease in quarterly net sales reflects a 3% negative impact from foreign currency translation partially offset by a 1% increase in sales volume.  For the full year net sales increased 4% primarily due to 3% volume growth. 

Segment Results

Total segment operating income decreased $2.4 million, or 5%, versus the prior year quarter.  Full year segment operating income was flat year over year. 

• Surfactant net sales were $323.2 million for the quarter, essentially flat versus prior year. Sales volume increased 2%, mostly due to higher demand in the consumer product end markets. The translation impact of a stronger U.S. dollar decreased net sales by 2%. Selling prices were flat versus the prior year quarter. Surfactant operating income increased $3.1 million or 11% versus the prior year, primarily due to higher sales volume combined with improved product mix and lower manufacturing costs in North America.
  
  
• Polymer net sales were $123.0 million in the fourth quarter, down 6% versus prior year. Total sales volume declined 4% principally due to lower European rigid polyol volumes. The translation impact of a stronger U.S. dollar negatively impacted net sales by 2% while selling prices were flat quarter over quarter. Operating income decreased $8.3 million or 44% versus the prior year quarter mostly due to lower volume, margin pressures and $2.1 million of higher costs associated with a scheduled phthalic anhydride maintenance shutdown.
  
  
• Specialty Product net sales were $20.5 million for the quarter, a 10% increase versus the prior year. Operating income increased $2.9 million versus the prior year quarter primarily due to favorable order timing differences within our pharmaceutical business, which compensated for a portion of the first half shortfall, and higher volume and margins in our food business.

Corporate Expenses

 

• Corporate expenses, excluding deferred compensation and business restructuring expenses, decreased $2.5 million, or 14%, versus the prior year quarter. This quarterly decrease was mostly due to nonrecurring 2017 legal expenses. Corporate expenses increased $3.4 million, or 6%, on a full year basis. This full year increase is primarily due to higher salaries and employee separation costs.

Income Taxes

The full year effective tax rate was 19.4% in 2018 compared to 34.3% in 2017.  This decrease was primarily attributable to: (i) a lower U.S. statutory tax rate of 21% in 2018 versus 35% in 2017; and (ii) the nonrecurrence of a $14.9 million net tax cost in 2017 resulting from the U.S. tax reform.  The U.S. tax reform provided a net annual benefit of approximately $10.6 million in 2018 versus the prior year.  We expect the effective tax rate to be in the range of 22% to 25% in 2019.   

Shareholder Return

The Company paid $5.6 million of dividends to shareholders in the fourth quarter.  For the full year the Company paid $20.9 million of dividends and repurchased $15.5 million of Company stock.  The Company has 494,287 shares remaining under its Board of Directors' share repurchase authorization.  With the increased cash dividend in the fourth quarter of 2018, the Company increased its dividend on the Company's common stock for the 51^st consecutive year.

Selected Balance Sheet Information

The Company's net debt level decreased $36.3 million for the quarter while the net debt ratio decreased from 2% to -3%, reflecting cash balances in excess of total debt.  The decrease in net debt was attributable to a $26.2 million increase in cash combined with a $10.1 million decline in total debt. 

The major working capital components were:

The Company had full year capital expenditures of $86.6 million in 2018 versus $78.6 million in the prior year.

Outlook

"After record results in each of the past three years, we believe our Surfactant business will continue to benefit from our diversification efforts into functional products, new technologies, improved internal efficiencies and expanded sales into our broad customer base globally.  We believe our Polymer business will benefit from the growing market for insulation materials and we are optimistic the business will deliver both full year volume growth and incremental margin improvement versus 2018.  Specialty Products should also improve," said F. Quinn Stepan, Jr., Chairman, President and Chief Executive Officer. 

Conference Call

Stepan Company will host a conference call to discuss its fourth quarter and full year 2018 results at 10:00 a.m. ET (9:00 a.m. CT) on February 21, 2019. The call can be accessed by phone and webcast. Telephone access will be available by dialing +1 (800) 750-5857, and the webcast can be accessed through the Investor Relations/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

Supporting Slides

Slides supporting this press release will be made available at www.stepan.com at the InvestorRelations page at approximately the same time as this press release is issued.

Corporate Profile

Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries.  Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning compounds and in agricultural and oilfield solutions.  The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

Headquartered in Northfield, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.

The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL.  For more information about Stepan Company please visit the Company online at www.stepan.com

* * * * *

Tables follow

Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K and Form 10-Q reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to disruptions in production or accidents at manufacturing facilities, global competition, volatility of raw material and energy costs, disruptions in transportation or significant changes in transportation costs, reduced demand due to customer product reformulations or new technologies, the probability of future acquisitions and the uncertainties related to the integration of acquired businesses, maintaining and protecting intellectual property rights, international business risks, including currency exchange rate fluctuations, legal restrictions and taxes, our ability to estimate and maintain appropriate levels of recorded liabilities, our debt covenants, our ability to access capital markets, downturns in certain industries and general economic downturns, global political, military, security or other instability, costs related to expansion or other capital projects, interruption or breaches of information technology systems, the costs and other effects of governmental regulation and legal and administrative proceedings and our ability to retain executive management and key personnel.

These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

 

 

 

 

 

View original content:http://www.prnewswire.com/news-releases/stepan-reports-fourth-quarter-and-record-full-year-2018-results-300799343.html

SOURCE Stepan Company

Luis E. Rojo, (847) 446-7500